Overview
Cortagen (EDRA) is a synthetic four-amino-acid peptide bioregulator engineered to target the cerebral cortex, peripheral nerves, and central nervous system.
What problem it targets: It targets brain damage, peripheral nerve injuries, post-stroke rehabilitation, chronic encephalopathy, and depressed neuroplastic function.
What It Does
• Stimulates brain cortical regeneration: Interacts directly with DNA in cortical brain cells to upregulate the expression of neurotrophic factors and structural nerve proteins.
• Accelerates peripheral nerve repair: Promotes axonal sprouting and myelin sheath recovery in damaged peripheral nerves, improving motor function and sensory conductivity.
• Exerts potent neuroprotective action: Reduces neuronal cell death following ischemic stroke or traumatic impact, accelerating functional rehabilitation.
• Realistic expectations: Typically run in 10- to 20-day cycles. Users observe progressive improvements in mental clarity, motor coordination, and nerve recovery across courses.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Rat sciatic-nerve repair | Daily intramuscular administration for 10 days | 10 micrograms/kg | Animal study after nerve transection and repair; no human dose conversion. |
| Cultured human lymphocytes | Added after 24 hours; 72-hour culture endpoint | 0.01 microgram/mL | 2023 chromatin experiment; exposure concentration in culture medium. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
